News Quantified

PRLD – prelude therapeutics incorporated (US:NASDAQ)

Prelude Therapeutics Incorporated (NASDAQ: PRLD) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating. They now have a $3.00 price target on the stock.

6/3

07:10 am

prld

Medium

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences [Yahoo! Finance]

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}